Prevalence Rate of Galactorrhea among Sudanese Hyperprolactinemic Infertile Women, Who Attended Reproductive Health Care Center –Khartoum (2005-2010)
Abstract
This was a prospective study conducted at Reproductive Health Care Center in Khartoum State during the period from 2005 to 2010 to determine prevalence rate of galactorrhea, among infertile women with hyperprolactinemia. The study protocol was approved by the local research Ethics Committees of the Sudan Fertility Association Care, Project of Reproductive Research. No data existed about incidence and prevalence of hyperprolactinemia and galactorrhea in Sudanese infertile women. For this purpose the study targeted infertile women visiting center. The women were screened, to determine the prevalence of hyperprolactinemia among infertile women, which was carried out in Reproductive Health Care Center Khartoum state from 2005 to 2010. The investigation was based on determination of prolactin levels and the prevalence of hyperprolactinemia in the infertile women within the reproductive age (18-45 year). An overall hyperprolactinemia was represented in 29% of total number of 14102 infertile women included in this study. The prevalence of hyperprolactinemia among women with galactorrhea was 74.8%. During the last year of study of 49 women from 105 hyperprolactinemic women with Amenorrhea, 27 (50%) were suffering galactorrhea, and were treated by bromocriptine. Another 22 (43%) women from 51 treated by Cabergoline contracted galactorrhea, during the monitoring and follow up of hyperprolactinemic women. The duration of Galactorrhoea disappearance per weeks was insignificant while the dosage of subsidence of galactorrhoea was highly statistically significant with a P-value = 0.00. Galactorrhea disappeared in all women 100% having galactorrhea in all study groups. These findings raise interesting questions about etiology of infertility and disease course of hyperprolactinemia that induces galactorrhea.
References
2. Bankowski BJ, Zacur HA (2003): Dopamine agonist therapy for hyperprolactinemia. Clin Obstet Gynecol 46:349–62.
3. Barkan A, Bronstein MD, Bruno OD (2010): Management of acromegaly in Latin America: expert panel recommendations Pituitary 13:168–175.
4. Biller BM (1999): Hyperprolactinemia. Int J Fertil Women’s Med 44: 74-77.
5. Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005): Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63:26–31.
6. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A (2006): Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin E ndocrinol (Oxf) 65:265–273.
7. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003): Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349:2023–2033.
8. Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008b): Medical therapy for clinically nonfunctioning pituitary adenomas. E ndocr Relat Cancer 15:905–915.
9. David M. Slovik E (2009): Evaluation of Galactorrhea and Hyperprolactinemia, Lipplincott Williams and wilkins. Chapter 100.
10. Ezzat S, Asa SL, Couldwell WT, Bare CE, Vance ML, McCutcheon IE (2004): The prevalence of pituitary adenomas: a systematic review. Cancer 101: 613-619.
